In This Article:
NEW YORK, Dec. 10, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 20, 2021.
The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
The following 129 securities will be added to the Index:
| Exchange | Ticker | Company |
| Nasdaq | BTX | Brooklyn ImmunoTherapeutics, Inc. |
| Nasdaq | LXRX | Lexicon Pharmaceuticals, Inc. |
| Nasdaq | CRIS | Curis, Inc. |
| Nasdaq | HBIO | Harvard Bioscience, Inc. |
| Nasdaq | EYPT | EyePoint Pharmaceuticals, Inc. |
| Nasdaq | MTEM | Molecular Templates, Inc. |
| Nasdaq | VIRX | Viracta Therapeutics, Inc. |
| Nasdaq | AVXL | Anavex Life Sciences Corp. |
| Nasdaq | INFI | Infinity Pharmaceuticals, Inc. |
| Nasdaq | HROW | Harrow Health, Inc. |
| Nasdaq | TNXP | Tonix Pharmaceuticals Holding Corp. |
| Nasdaq | CMRX | Chimerix, Inc. |
| Nasdaq | ADMA | ADMA Biologics Inc |
| Nasdaq | SESN | Sesen Bio, Inc. |
| Nasdaq | CLSD | Clearside Biomedical, Inc. |
| Nasdaq | PRQR | ProQR Therapeutics N.V. |
| Nasdaq | ALPN | Alpine Immune Sciences, Inc. |
| Nasdaq | ACRS | Aclaris Therapeutics, Inc. |
| Nasdaq | NVCR | NovoCure Limited |
| Nasdaq | MRUS | Merus N.V. |
| Nasdaq | OCX | Oncocyte Corporation |
| Nasdaq | CRVS | Corvus Pharmaceuticals, Inc. |
| Nasdaq | LPTX | Leap Therapeutics, Inc. |
| Nasdaq | OBSV | ObsEva SA |
| Nasdaq | MBIO | Mustang Bio, Inc. |
| Nasdaq | OPTN | OptiNose, Inc. |
| Nasdaq | SLDB | Solid Biosciences Inc. |
| Nasdaq | NRXP | NRX Pharmaceuticals, Inc. |
| Nasdaq | EOLS | Evolus, Inc. |
| Nasdaq | COGT | Cogent Biosciences, Inc. |
| Nasdaq | MREO | Mereo BioPharma Group plc |
| Nasdaq | AQST | Aquestive Therapeutics, Inc. |
| Nasdaq | EVLO | Evelo Biosciences, Inc. |
| Nasdaq | VRCA | Verrica Pharmaceuticals Inc. |
| Nasdaq | GRTS | Gritstone bio, Inc. |
| Nasdaq | INBX | Inhibrx, Inc. |
| Nasdaq | BCYC | Bicycle Therapeutics plc |
| Nasdaq | CDAK | Codiak BioSciences, Inc. |
| Nasdaq | MIRM | Mirum Pharmaceuticals, Inc. |
| Nasdaq | IMPL | Impel NeuroPharma, Inc. |
| Nasdaq | MORF | Morphic Holding, Inc. |
| Nasdaq | OYST | Oyster Point Pharma, Inc. |
| Nasdaq | ETNB | 89bio, Inc. |
| Nasdaq | PHAT | Phathom Pharmaceuticals, Inc. |
| Nasdaq | FDMT | 4D Molecular Therapeutics, Inc. |
| Nasdaq | CVAC | CureVac N.V. |
| Nasdaq | HRMY | Harmony Biosciences Holdings, Inc. |
| Nasdaq | VTRS | Viatris Inc. |
| Nasdaq | QSI | Quantum-Si Incorporated |
| Nasdaq | PMVP | PMV Pharmaceuticals, Inc. |
| Nasdaq | KYMR | Kymera Therapeutics, Inc. |
| Nasdaq | NAUT | Nautilus Biotechnology, Inc. |
| Nasdaq | DYN | Dyne Therapeutics, Inc. |
| Nasdaq | CCCC | C4 Therapeutics, Inc. |
| Nasdaq | HUMA | Humacyte, Inc. |
| Nasdaq | ATHA | Athira Pharma, Inc. |
| Nasdaq | LABP | Landos Biopharma, Inc. |
| Nasdaq | TSHA | Taysha Gene Therapies, Inc. |
| Nasdaq | ONCR | Oncorus, Inc. |
| Nasdaq | PRAX | Praxis Precision Medicines, Inc. |
| Nasdaq | CMPS | COMPASS Pathways Plc |
| Nasdaq | PRLD | Prelude Therapeutics Incorporated |
| Nasdaq | BOLT | Bolt Biotherapeutics, Inc. |
| Nasdaq | ABCM | Abcam plc |
| Nasdaq | STTK | Shattuck Labs, Inc. |
| Nasdaq | KRON | Kronos Bio, Inc. |
| Nasdaq | ALGS | Aligos Therapeutics, Inc. |
| Nasdaq | AVIR | Atea Pharmaceuticals, Inc. |
| Nasdaq | OLMA | Olema Pharmaceuticals, Inc. |
| Nasdaq | SBTX | Silverback Therapeutics, Inc. |
| Nasdaq | MRVI | Maravai LifeSciences Holdings, Inc. |
| Nasdaq | BCAB | BioAtla, Inc. |
| Nasdaq | GRCL | Gracell Biotechnologies Inc. |
| Nasdaq | KNTE | Kinnate Biopharma Inc. |
| Nasdaq | SEER | Seer, Inc. |
| Nasdaq | ME | 23andMe Holding Co. |
| Nasdaq | KMPH | KemPharm, Inc. |
| Nasdaq | BVS | Bioventus Inc. |
| Nasdaq | SNSE | Sensei Biotherapeutics, Inc. |
| Nasdaq | SABS | SAB Biotherapeutics, Inc. |
| Nasdaq | VOR | Vor Biopharma Inc. |
| Nasdaq | ABCL | AbCellera Biologics Inc. |
| Nasdaq | CGEM | Cullinan Oncology, Inc. |
| Nasdaq | DBTX | Decibel Therapeutics, Inc. |
| Nasdaq | CNTB | Connect Biopharma Holdings Limited |
| Nasdaq | SANA | Sana Biotechnology, Inc. |
| Nasdaq | ACHL | Achilles Therapeutics plc |
| Nasdaq | IKNA | Ikena Oncology, Inc. |
| Nasdaq | TERN | Terns Pharmaceuticals, Inc. |
| Nasdaq | EWTX | Edgewise Therapeutics, Inc. |
| Nasdaq | RXRX | Recursion Pharmaceuticals, Inc. |
| Nasdaq | RXDX | Prometheus Biosciences, Inc. |
| Nasdaq | TIL | Instil Bio, Inc. |
| Nasdaq | DSGN | Design Therapeutics, Inc. |
| Nasdaq | BMEA | Biomea Fusion, Inc. |
| Nasdaq | RAIN | Rain Therapeutics Inc. |
| Nasdaq | ATAI | ATAI Life Sciences N.V. |
| Nasdaq | CADL | Candel Therapeutics, Inc. |
| Nasdaq | HOWL | Werewolf Therapeutics, Inc. |
| Nasdaq | TALS | Talaris Therapeutics, Inc. |
| Nasdaq | CYT | Cyteir Therapeutics, Inc. |
| Nasdaq | OMIC | Singular Genomics Systems, Inc. |
| Nasdaq | DNAY | Codex DNA, Inc. |
| Nasdaq | CNTA | Centessa Pharmaceuticals plc |
| Nasdaq | IMGO | Imago BioSciences, Inc. |
| Nasdaq | IPSC | Century Therapeutics, Inc. |
| Nasdaq | SERA | Sera Prognostics, Inc. |
| Nasdaq | RANI | Rani Therapeutics Holdings, Inc. |
| Nasdaq | VERV | Verve Therapeutics, Inc. |
| Nasdaq | DAWN | Day One Biopharmaceuticals, Inc. |
| Nasdaq | JANX | Janux Therapeutics, Inc. |
| Nasdaq | TKNO | Alpha Teknova, Inc. |
| Nasdaq | GLUE | Monte Rosa Therapeutics, Inc. |
| Nasdaq | RPID | Rapid Micro Biosystems, Inc. |
| Nasdaq | AVTE | Aerovate Therapeutics, Inc. |
| Nasdaq | ERAS | Erasca, Inc. |
| Nasdaq | TNYA | Tenaya Therapeutics, Inc. |
| Nasdaq | ICVX | Icosavax, Inc. |
| Nasdaq | IMRX | Immuneering Corporation |
| Nasdaq | RLYB | Rallybio Corporation |
| Nasdaq | GRPH | Graphite Bio, Inc. |
| Nasdaq | ABOS | Acumen Pharmaceuticals, Inc. |
| Nasdaq | LYEL | Lyell Immunopharma, Inc. |
| Nasdaq | ABSI | Absci Corporation |
| Nasdaq | NUVL | Nuvalent, Inc. |
| Nasdaq | OMGA | Omega Therapeutics, Inc. |
| Nasdaq | CRBU | Caribou Biosciences, Inc. |
| Nasdaq | MXCT | MaxCyte, Inc. |
| Nasdaq | BLU | BELLUS Health Inc. |
As a result of the reconstitution, the following 21 securities will be removed from the Index: